title: Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia.
abstract: The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 ± 3.9 months for 'low' expressed and 7.5 ± 5.6 months for 'high' expressed group, p<0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 ± 3.6 months for 'low' and 8.4 ± 2.7 months for 'high' expressed group, p<0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 ± 2.8 months for 'low' and 9.8 ± 1.1 months for 'high' expressed group, p<0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress".
authors.affiliation: Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: f.kryukov@gmail.com.
authors.forename: Fedor
authors.initials: F
authors.lastname: Kryukov
authors.forename: Elena
authors.initials: E
authors.lastname: Dementyeva
authors.forename: Lenka
authors.initials: L
authors.lastname: Kubiczkova
authors.forename: Jiri
authors.initials: J
authors.lastname: Jarkovsky
authors.forename: Lucie
authors.initials: L
authors.lastname: Brozova
authors.forename: Jakub
authors.initials: J
authors.lastname: Petrik
authors.forename: Pavel
authors.initials: P
authors.lastname: Nemec
authors.forename: Sabina
authors.initials: S
authors.lastname: Sevcikova
authors.forename: Jiri
authors.initials: J
authors.lastname: Minarik
authors.forename: Zdena
authors.initials: Z
authors.lastname: Stefanikova
authors.forename: Petr
authors.initials: P
authors.lastname: Kuglik
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002453:Cell Cycle / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics* / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018816:Genes, cdc; D006367:HeLa Cells; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000235:genetics*; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16
keywords: Cell cycle genes; Multiple myeloma; Overall survival; Plasma cell leukemia; Time-to-progression